SiSaf’s Bio-Courier Technology Enables Clinical Trial Success for Topical Treatment of Mild to Moderate Alopecia Areata

0
38
SiSaf, Ltd. announced that a licensee of the ProSilic® variant of its technology has reported positive topline results from a randomized, placebo-controlled, multi-dose Phase II trial evaluating its topical treatment for mild to moderate alopecia areata, commonly known as spot baldness.
[SiSag, Ltd.]
Press Release